JP2025508792A - ジペプチジルペプチダーゼ阻害化合物の塩及び結晶形態 - Google Patents

ジペプチジルペプチダーゼ阻害化合物の塩及び結晶形態 Download PDF

Info

Publication number
JP2025508792A
JP2025508792A JP2024549554A JP2024549554A JP2025508792A JP 2025508792 A JP2025508792 A JP 2025508792A JP 2024549554 A JP2024549554 A JP 2024549554A JP 2024549554 A JP2024549554 A JP 2024549554A JP 2025508792 A JP2025508792 A JP 2025508792A
Authority
JP
Japan
Prior art keywords
salt
crystalline form
formula
compound
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024549554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508792A5 (https=
Inventor
ジアン ファン、
イン ドウ、
ジェン ゴン、
フェンフェイ ヂュ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haisco Pharmaceuticals Pte Ltd
Original Assignee
Haisco Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haisco Pharmaceuticals Pte Ltd filed Critical Haisco Pharmaceuticals Pte Ltd
Publication of JP2025508792A publication Critical patent/JP2025508792A/ja
Publication of JP2025508792A5 publication Critical patent/JP2025508792A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cooling Or The Like Of Semiconductors Or Solid State Devices (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024549554A 2022-02-22 2023-02-21 ジペプチジルペプチダーゼ阻害化合物の塩及び結晶形態 Pending JP2025508792A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210160862.5 2022-02-22
CN202210160862 2022-02-22
PCT/CN2023/077409 WO2023160542A1 (zh) 2022-02-22 2023-02-21 二肽基肽酶抑制剂化合物的盐及晶型

Publications (2)

Publication Number Publication Date
JP2025508792A true JP2025508792A (ja) 2025-04-10
JP2025508792A5 JP2025508792A5 (https=) 2026-02-27

Family

ID=87764787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024549554A Pending JP2025508792A (ja) 2022-02-22 2023-02-21 ジペプチジルペプチダーゼ阻害化合物の塩及び結晶形態

Country Status (13)

Country Link
US (1) US20250188067A1 (https=)
EP (1) EP4484414A4 (https=)
JP (1) JP2025508792A (https=)
KR (1) KR20240153351A (https=)
CN (1) CN118660873A (https=)
AU (1) AU2023225835A1 (https=)
CA (1) CA3243683A1 (https=)
CL (1) CL2024002490A1 (https=)
IL (1) IL314852A (https=)
MX (1) MX2024010180A (https=)
TW (1) TW202342466A (https=)
WO (1) WO2023160542A1 (https=)
ZA (1) ZA202407225B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314855A (en) * 2022-02-22 2024-10-01 Haisco Pharmaceuticals Pte Ltd Preparation method of nitrogen-containing heterocyclic compound
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
NO2699580T3 (https=) * 2014-01-24 2018-02-24
CN115996923B (zh) * 2020-08-26 2025-07-18 海思科医药集团股份有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN114106005B (zh) * 2020-08-26 2025-08-01 西藏海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
US20240150335A1 (en) * 2021-02-05 2024-05-09 Medshine Discovery Inc. Fused ring derivatives containing 1,4-oxazepane

Also Published As

Publication number Publication date
EP4484414A4 (en) 2026-01-28
WO2023160542A1 (zh) 2023-08-31
AU2023225835A1 (en) 2024-10-03
ZA202407225B (en) 2025-12-17
CN118660873A (zh) 2024-09-17
EP4484414A1 (en) 2025-01-01
CL2024002490A1 (es) 2024-12-13
MX2024010180A (es) 2024-08-27
TW202342466A (zh) 2023-11-01
IL314852A (en) 2024-10-01
US20250188067A1 (en) 2025-06-12
KR20240153351A (ko) 2024-10-22
CA3243683A1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
JP2012518623A (ja) Ｃｏｐｄの処置に有用な５−ピラゾリル−２−ピリドン誘導体のトシル酸塩
EP4484424A1 (en) Dipeptidyl peptidase 1 inhibitor polymorph, preparation method and use therefor
JP2025508792A (ja) ジペプチジルペプチダーゼ阻害化合物の塩及び結晶形態
KR101557832B1 (ko) (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
EP1853232B1 (en) Stable crystalline form of bifeprunox mesylate, dosage forms thereof adn methods for using them
US12384784B2 (en) Polymorphs of Acalabrutinib, a Bruton's tyrosine kinase inhibitor
CN116041324B (zh) 一种氘代吡唑二氯苯甲酰胺类化合物、药物组合物和用途
WO2025144118A1 (en) Novel polymorph of ribociclib dihydrochloride dihydrate and method of preparation
HUP0100343A2 (hu) A 2-{2-[4[bisz-(4-fluor-fenil)-metil]-1-piperazinil]-etoxi}-ecetsav-dihidroklorid új pszeudopolimorf kristályos formái, azok előállítására alkalmas eljárások és ilyen kristályos formákat tartalmazó gyógyszerkészítmények
JP7187733B2 (ja) オクタヒドロチエノキノリン化合物のコハク酸塩及びその結晶
JP2025530530A (ja) カレバスチン－ｐ－トルエンスルホン酸塩の結晶形及び無定形
EA053095B1 (ru) Соль и кристаллическая форма соединения, являющегося ингибитором дипептидилпептидазы
US20220009929A1 (en) Polymorphic forms of ibrutinib
JP7671362B2 (ja) 医薬組成物、その製造方法及び使用
EP3412661A1 (en) Cocrystals of vortioxetine hydrobromide and resorcinol
EP4667465A1 (en) Salt of benzo-nitrogen heteroaromatic ring derivative, crystalline form, and pharmaceutical use thereof
EP3517529B1 (en) Salt of quinazoline derivative, preparation method therefor and application thereof
HK40121338A (zh) 一种嘧啶苯胺类化合物的晶型、制备方法及应用
TW202535412A (zh) Pde4b抑制劑的晶型及其在醫藥上的用途
WO2025090032A1 (en) Novel polymorph of cabozantinib l-tartrate (form a) and method of preparation
EA051477B1 (ru) Полиморф ингибитора дипептидилпептидазы 1, способ его получения и применение
CN116396305A (zh) 一种稠环衍生物的晶型、其制备方法及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260205